FDA Approves COBENFY How Segal Trials are Transforming Schizophrenia Treatment
SSegal Trials is proud to have played a significant role in the FDA approval of COBENFY™ (xanomeline and trospium chloride), a pioneering first-in-class muscarinic agonist developed by Bristol Myers Squibb…
AHF Urges Wider Availability of Lenacapavir for Global HIV Treatment
The AIDS Healthcare Foundation (AHF) has expressed support for Gilead’s recent decision to expand the availability of lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with…
FDA Approves Neoadjuvant Opdivo and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for adult patients with resectable non-small cell lung cancer (NSCLC) characterized by…
Marshall B. Ketchum University Hosts Second Annual Alumni Homecoming & Awards
Marshall B. Ketchum University (MBKU) recently celebrated the outstanding achievements of its alumni at the 2024 Distinguished Alumni Awards Ceremony, held during its second annual homecoming event. This year, the…
Halozyme Expands Global Collaboration and Licensing Agreement with Argenx for ENHANZE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced that argenx has identified four new targets under their global collaboration and license agreement. This agreement grants argenx exclusive access to Halozyme’s ENHANZE®…
GigaGen Secures U.S. BARDA Contract to Develop Antibody Therapies for Botulinum Neurotoxins and Biothreats
GigaGen Inc., a biotechnology firm specializing in innovative antibody treatments for immunodeficiencies, infectious diseases, and cancers resistant to checkpoint inhibitors, has announced a new contract awarded by the Biomedical Advanced…
Teva and mAbxience Strengthen Partnership with New Oncology Biosimilar Candidate
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and mAbxience, a majority-owned group by Fresenius Kabi with partial ownership from Insud Pharma, have…
Announcement of Sales Partnership Agreement with Nxera Pharma Japan for Insomnia Treatment ‘QUVIVIQ
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) has announced the conclusion of a sales partnership agreement with Nxera Pharma Japan Co., Ltd. (hereafter…
Allergan Aesthetics & Girls Inc. Mark 6 Years, Urge Pledge for STEM Mentorship
Allergan Aesthetics, a part of AbbVie, has announced its sixth consecutive year of partnering with Girls Inc. to encourage high school and college girls’ interest in STEM (science, technology, engineering,…
Gilead Partners with Six Generics for Royalty-Free Licensing of Lenacapavir in High-Incidence HIV Regions
Gilead Sciences, Inc. (Nasdaq: GILD) has announced the signing of non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to produce and distribute generic lenacapavir in 120 high-incidence, resource-limited countries,…
FDA Approves Opdivo with Chemotherapy for Resectable NSCLC Treatment
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for the treatment of adult patients with resectable non-small cell lung…
La La Anthony Teams Up with Amgen to Share How Plaque Psoriasis Impacts Her Life
Amgen (NASDAQ: AMGN) has teamed up with actress, producer, and entrepreneur La La Anthony to highlight her personal experience with plaque psoriasis and inspire others to have open conversations with…